Erasca Securities Class Action
Erasca · Erasca common stock and ERAS-0015 · Ongoing Litigation
About this case
Investors allege that Erasca and certain executives violated federal securities laws by making materially false or misleading statements and omitting information concerning the preclinical data and patent and trade-secret risks associated with its ERAS-0015 product. The matter is pending in the U.S. District Court for the Southern District of California.
Case overview
- Defendant company
- Erasca
- Product or service
- Erasca common stock and ERAS-0015
- Case name
- Cheng v. Erasca, Inc.
- Court case number
- 26-cv-03481 (S.D. Cal.)
- Case status
- Ongoing Litigation
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Important dates
- Lead plaintiff application
Participation information
Lead plaintiff application
Investors who purchased Erasca shares between January 14, 2025 and April 26, 2026, inclusive, and allegedly suffered losses could have sought appointment as lead plaintiff.
The deadline to request appointment as lead plaintiff was August 10, 2026. The notice states that serving as lead plaintiff was not required to share in any recovery.
- Type
- Lead Plaintiff
- Status
- Deadline passed
- Reported proof requirement
- Unclear
Sources
- Erasca Securities Class Action
Barchart.com ·
- Erasca Securities Class Action
Barchart.com ·
- Erasca Securities Class Action Concerning Alleged Misleading Statements
Barchart.com ·
- Erasca Securities Class Action
Barchart.com ·
- Erasca Securities Class Action
Barchart.com ·
- Erasca Securities Class Action
Barchart.com ·